Vaxart to Showcase Oral Vaccine Platform at H.C. Wainwright Conference
Event summary
- Vaxart to present at H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026.
- Live webcast available on Vaxart’s investor relations website.
- Replay of presentation accessible for 30 days post-event.
- Vaxart develops oral recombinant vaccines using proprietary pill delivery platform.
- Current pipeline includes vaccines for coronavirus, norovirus, influenza, and HPV.
The big picture
Vaxart’s participation in the H.C. Wainwright conference underscores the growing interest in innovative vaccine delivery platforms. The company’s oral recombinant vaccines, which eliminate the need for refrigeration and needle administration, position it uniquely in the biotech sector. As the industry shifts toward more accessible and scalable vaccine solutions, Vaxart’s technology could play a pivotal role in addressing global health challenges.
What we're watching
- Pipeline Progress
- How Vaxart’s oral vaccine candidates advance through clinical stages.
- Market Differentiation
- Whether Vaxart’s needle-free, refrigeration-free platform gains traction.
- Investor Sentiment
- The impact of conference presentations on Vaxart’s valuation.
Related topics